| Literature DB >> 22385678 |
Sahar Melamed1, Chaim Lalush, Tal Elad, Sharon Yagur-Kroll, Shimshon Belkin, Rami Pedahzur.
Abstract
The ever-growing use of pharmaceutical compounds, including antibacterial substances, poses a substantial pollution load on the environment. Such compounds can compromise water quality, contaminate soils, livestock and crops, enhance resistance of microorganisms to antibiotic substances, and hamper human health. We report the construction of a novel panel of genetically engineered Escherichia coli reporter strains for the detection and classification of antibiotic substances. Each of these strains harbours a plasmid that carries a fusion of a selected gene promoter to bioluminescence (luxCDABE) reporter genes and an alternative tryptophan auxotrophy-based non-antibiotic selection system. The bioreporter panel was tested for sensitivity and responsiveness to diverse antibiotic substances by monitoring bioluminescence as a function of time and of antibiotic concentrations. All of the tested antibiotics were detected by the panel, which displayed different response patterns for each substance. These unique responses were analysed by several algorithms that enabled clustering the compounds according to their functional properties, and allowed the classification of unknown antibiotic substances with a high degree of accuracy and confidence.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22385678 PMCID: PMC3815330 DOI: 10.1111/j.1751-7915.2012.00333.x
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 5.813
Figure 1Plasmids pBR2TTS (A) and pBRlux‐trp (B) with the relevant restriction sites. (C) Plasmid pBRlux‐trp restores the ability of the E. coliΔtrpE strain (SM335) to grow on a tryptophan‐free medium (bottom), where the E. coliΔtrpE strain (SM301) does not grow (top).
Escherichia coli strains used in this study
| Strain | Host | Plasmid | Phenotype/genotype | Sensing element information | Reference |
|---|---|---|---|---|---|
| DH5α | – | – | F‐ | – | |
| JW1256 | BW25113 | – | – | ||
| SM301 | BW25113 | – | – | Current work | |
| SM309 | DH5α | – | – | Current work | |
| SM332 | SM301 | pBRlux‐trp: | Cytoplasmatic membrane fusion protein, subunit of EmrAB‐TolC multidrug efflux transport system | Current work | |
| SM333 | SM301 | pBRlux‐trp: | Periplasmic lipoprotein component of the AcrAB‐TolC multidrug efflux pump | Current work | |
| SM334 | SM301 | pBRlux‐trp: | G6PDH, regulated by SoxS and MarA | Current work | |
| SM335 | SM301 | pBRlux‐trp: | Dual transcriptional activator, participates in the removal of antibiotics | Current work | |
| SM337 | SM301 | pBRlux‐trp: | Outer membrane porin involved in the efflux transport system | Current work | |
| SM338 | SM301 | pBRlux‐trp: | pH‐inducible protein involved in stress response | Current work | |
| SM340 | SM301 | pBRlux‐trp:zntA | Lead, cadmium, zinc and mercury transporting ATPase | Current work | |
| SM341 | SM301 | pBRlux‐trp: | Multiple antibiotic resistance protein | Current work | |
| SM342 | SM301 | pBRlux‐trp: | DNA recombination protein, induce the SOS response to DNA damage | Current work | |
| SM343 | SM301 | pBRlux‐trp: | Antisense regulator of the translation of the OmpF porin, under SoxS regulation | Current work | |
| SM344 | SM301 | pBRlux‐trp: | Bifunctional hydroperoxidase I, having both catalase and peroxidase activity | Current work | |
| SM345 | SM301 | pBRlux‐trp: | Superoxide dismutase protein | Current work | |
| SM346 | SM301 | pBRlux‐trp: | RNA polymerase, beta subunit | Current work | |
| SM347 | SM301 | pBRlux‐trp: | Outer membrane porin | Current work |
Constituents of the final 12‐member reporter panel.
Antibiotic substances used in this study
| No. | Antibiotic | Group | Mode of action |
|---|---|---|---|
| 1 | Tetracycline | Tetracyclines | Protein synthesis inhibitor (30S) |
| 2 | Oxytetracycline | Tetracyclines | Protein synthesis inhibitor (30S) |
| 3 | Sulfamethoxazole | Sulfonamides | Folic acid metabolism inhibitor |
| 4 | Sulfadimethoxine | Sulfonamides | Folic acid metabolism inhibitor |
| 5 | Ampicillin | β‐lactams | Cell wall synthesis inhibitor |
| 6 | Amoxicillin | β‐lactams | Cell wall synthesis inhibitor |
| 7 | Nalidixic Acid | Quinolones | DNA gyrase inhibitor |
| 8 | Chloramphenicol | Phenicols | Protein synthesis inhibitor (50S) |
| 9 | Rifampin | Rifamycins | RNA polymerase inhibitor |
| 10 | Puromycin | Puromycin | Protein synthesis inhibitor (tRNA) |
| 11 | Colistin | Polymyxins | Cytoplasmic membrane disruptor |
| 12 | Ciprofloxacin | Quinolones | DNA gyrase inhibitor |
| 13 | Sulfisoxazole | Sulfonamides | Folic acid metabolism inhibitor |
| 14 | Polymyxin B | Polymyxins | Cytoplasmic membrane disruptor |
| 15 | Doxycycline | Tetracyclines | Protein synthesis inhibitor (30S) |
| 16 | Thiamphenicol | Phenicols | Protein synthesis inhibitor (50S) |
Substances 1–11 were used for the original construction of the database; compounds 12–16 were employed as ‘unknowns’ for testing the classifiers.
Figure 2Maximal induction of soxS:luxCDABE by tetracycline, oxytetracycline and chloramphenicol (A) and of micF:luxCDABE by sulfamethoxazole, sulfadimethoxine and colistin (B) after 8 h of exposure. (C) Bioluminescent signal development of micF:luxCDABE induction by sulfamethoxazole (20 µg ml−1) and colistin (0.38 µg ml−1) as a function of time. (D) Maximal induction of emrA:luxCDABE by ampicillin and amoxicillin after 8 h of exposure. (E) Bioluminescent signal development of recA:luxCDABE by nalidixic acid as a function of time. Error bars indicate the standard error of the mean of three independent repeats.
Maximal induction of each reporter strain by each of the 11 antibiotics tested in the course of 10 h of exposure
Figure 3Clustering of the 11 antibiotics and additional 5 ‘unknown’ antibiotics by Spearman rank correlation coefficient based on the induction pattern of 12 reporter strains, following 5 h of exposure (the ‘unknown’ antibiotics are underlined and their branches are dotted).
Figure 4Response patterns of 12 reporter strains to 11 antibiotics, following a 5 h exposure. Error bars indicate the standard deviation of 20 independent repeats.
Classification errors (%) using the nearest neighbour algorithm. Error rate was calculated using the leaving‐one‐out method
| Time of exposure (h) | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Total errors | 22.5 | 9.17 | 6.25 | 9.17 | 4.58 | 3.75 | 7.92 |
| Class errors | 10 | 4.58 | 1.67 | 4.17 | 2.5 | 2.5 | 4.58 |
| False positive | 2.08 | 2.08 | 1.25 | 1.25 | 0 | 0 | 0.42 |
| False negative | 0 | 0.42 | 0 | 0 | 0 | 0 | 0 |
Classification of an antibiotic as an antibiotic from a different class.
Average error rate estimates of six classification algorithms and the majority voting tested in two modes: individual and class
| Algorithm | Individual | Class | ||
|---|---|---|---|---|
| Number of errors | % | Number of errors | % | |
| Nearest neighbour | 18 | 12.2 | 18 | 12.2 |
| Mahalanobis distance based | 16 | 10.9 | 28 | 19.0 |
| Linear Bayes – non‐diagonal | 42 | 28.6 | 42 | 28.6 |
| Linear Bayes – diagonal | 40 | 27.2 | 40 | 27.2 |
| Quadratic Bayes – non‐diagonal | 16 | 10.9 | 22 | 15.0 |
| Quadratic Bayes – diagonal | 24 | 16.3 | 22 | 15.0 |
| Majority voting | 11 | 7.5 | 6 | 4.1 |
Figure 5Classification of antibiotics, unfamiliar to the reporter panel, introduced to the classifiers. Classification using: (A) Linear Bayes – non‐diagonal with class database mode; (B) majority voting with class database mode. (N.D. = not detected)
Figure 6Average error rate estimates of six classification algorithms and the majority voting tested in class mode of the database in time‐dependent or ‐independent manner.
Figure 7Classification of seven different concentrations of tetracycline using the majority voting with the class database mode.